12,921 results on '"TUMOR diagnosis"'
Search Results
2. Artificial Intelligence-Based Thermal Imaging for Breast Tumor Location and Size Estimation Using Thermal Impedance.
- Author
-
Nascimento, Jefferson G., Menegaz, Gabriela L., and Guimaraes, Gilmar
- Subjects
- *
ARTIFICIAL intelligence , *CANCER cells , *TUMOR diagnosis , *INFRARED heating , *DEEP learning , *ANALYTIC geometry - Abstract
Tumors can be detected from a temperature gradient due to high vascularization and increased metabolic activity of cancer cells. Thermal infrared images have been recognized as potential alternatives to detect these tumors. However, even the use of artificial intelligence directly on these images has failed to accurately locate and detect the tumor size due to the low sensitivity of temperatures and position within the breast. Thus, we aimed to develop techniques based on applying the thermal impedance method and artificial intelligence to determine the origin of the heat source (abnormal cancer metabolism) and its size. The low sensitivity to tiny and deep tumors is circumvented by utilizing the concept of thermal impedance and artificial intelligence techniques such as deep learning. We describe the development of a thermal model and the creation of a database based on its solution. We also outline the choice of detectable parameters in the thermal image, the use of deep learning libraries, and network training using convolutional neural networks (CNNs). Lastly, we present tumor location and size estimates based on thermographic images obtained from simulated thermal models of a breast, using Cartesian geometry and a scanned geometric shape of an anatomical phantom model. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. DNA/RNA-based electrochemical nanobiosensors for early detection of cancers.
- Author
-
Mikaeeli Kangarshahi, Babak, Naghib, Seyed Morteza, and Rabiee, Navid
- Subjects
- *
RNA analysis , *TUMOR diagnosis , *DNA analysis , *COMMUNICABLE diseases , *NANOSTRUCTURES , *COST effectiveness , *PROSTATE-specific antigen , *EARLY detection of cancer , *MICRORNA , *BIOSENSORS , *TUMOR markers , *CELLULAR signal transduction , *NUCLEIC acids , *ELECTROCHEMICAL analysis , *TRANSDUCERS - Abstract
Nucleic acids, like DNA and RNA, serve as versatile recognition elements in electrochemical biosensors, demonstrating notable efficacy in detecting various cancer biomarkers with high sensitivity and selectivity. These biosensors offer advantages such as cost-effectiveness, rapid response, ease of operation, and minimal sample preparation. This review provides a comprehensive overview of recent developments in nucleic acid-based electrochemical biosensors for cancer diagnosis, comparing them with antibody-based counterparts. Specific examples targeting key cancer biomarkers, including prostate-specific antigen, microRNA-21, and carcinoembryonic antigen, are highlighted. The discussion delves into challenges and limitations, encompassing stability, reproducibility, interference, and standardization issues. The review suggests future research directions, exploring new nucleic acid recognition elements, innovative transducer materials and designs, novel signal amplification strategies, and integration with microfluidic devices or portable instruments. Evaluating these biosensors in clinical settings using actual samples from cancer patients or healthy donors is emphasized. These sensors are sensitive and specific at detecting non-communicable and communicable disease biomarkers. DNA and RNA's self-assembly, programmability, catalytic activity, and dynamic behavior enable adaptable sensing platforms. They can increase biosensor biocompatibility, stability, signal transduction, and amplification with nanomaterials. In conclusion, nucleic acids-based electrochemical biosensors hold significant potential to enhance cancer detection and treatment through early and accurate diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories.
- Author
-
González, Álvaro, López-Borrego, Silvia, Sandúa, Amaia, Vales-Gomez, Mar, and Alegre, Estibaliz
- Subjects
- *
TUMOR diagnosis , *EXTRACELLULAR vesicles , *PHENOMENOLOGICAL biology , *CELL physiology , *TUMOR markers , *BIOCHEMISTRY , *PATHOLOGICAL laboratories , *METABOLISM , *TUMORS , *DISEASE progression - Abstract
Extracellular vesicles (EVs) are nano-sized particles secreted by most cells. They transport different types of biomolecules (nucleic acids, proteins, and lipids) characteristic of their tissue or cellular origin that can mediate long-distance intercellular communication. In the case of cancer, EVs participate in tumor progression by modifying the tumor microenvironment, favoring immune tolerance and metastasis development. Consequently, EVs have great potential in liquid biopsy for cancer diagnosis, prognosis and follow-up. In addition, EVs could have a role in cancer treatment as a targeted drug delivery system. The intense research in the EV field has resulted in hundreds of patents and the creation of biomedical companies. However, methodological issues and heterogeneity in EV composition have hampered the advancement of EV validation trials and the development of EV-based diagnostic and therapeutic products. Consequently, only a few EV biomarkers have moved from research to clinical laboratories, such as the ExoDx Prostate IntelliScore (EPI) test, a CLIA/FDA-approved EV prostate cancer diagnostic test. In addition, the number of large-scale multicenter studies that would clearly define biomarker performance is limited. In this review, we will critically describe the different types of EVs, the methods for their enrichment and characterization, and their biological role in cancer. Then, we will specially focus on the parameters to be considered for the translation of EV biology to the clinic laboratory, the advances already made in the field of EVs related to cancer diagnosis and treatment, and the issues still pending to be solved before EVs could be used as a routine tool in oncology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker.
- Author
-
Kreis, Nina-Naomi, Moon, Ha Hyung, Wordeman, Linda, Louwen, Frank, Solbach, Christine, Yuan, Juping, and Ritter, Andreas
- Subjects
- *
TUMOR diagnosis , *RESEARCH funding , *CELL physiology , *TUMOR markers , *META-analysis , *CANCER patients , *SYSTEMATIC reviews , *GENE expression , *ONCOGENES , *CELL death , *KINESIN , *TUMORS , *PROGRESSION-free survival , *DISEASE progression , *GENOMES , *OVERALL survival ,TUMOR genetics - Abstract
KIF2C/MCAK (KIF2C) is the most well-characterized member of the kinesin-13 family, which is critical in the regulation of microtubule (MT) dynamics during mitosis, as well as interphase. This systematic review briefly describes the important structural elements of KIF2C, its regulation by multiple molecular mechanisms, and its broad cellular functions. Furthermore, it systematically summarizes its oncogenic potential in malignant progression and performs a meta-analysis of its prognostic value in cancer patients. KIF2C was shown to be involved in multiple crucial cellular processes including cell migration and invasion, DNA repair, senescence induction and immune modulation, which are all known to be critical during the development of malignant tumors. Indeed, an increasing number of publications indicate that KIF2C is aberrantly expressed in multiple cancer entities. Consequently, we have highlighted its involvement in at least five hallmarks of cancer, namely: genome instability, resisting cell death, activating invasion and metastasis, avoiding immune destruction and cellular senescence. This was followed by a systematic search of KIF2C/MCAK's expression in various malignant tumor entities and its correlation with clinicopathologic features. Available data were pooled into multiple weighted meta-analyses for the correlation between KIF2Chigh protein or gene expression and the overall survival in breast cancer, non-small cell lung cancer and hepatocellular carcinoma patients. Furthermore, high expression of KIF2C was correlated to disease-free survival of hepatocellular carcinoma. All meta-analyses showed poor prognosis for cancer patients with KIF2Chigh expression, associated with a decreased overall survival and reduced disease-free survival, indicating KIF2C's oncogenic potential in malignant progression and as a prognostic marker. This work delineated the promising research perspective of KIF2C with modern in vivo and in vitro technologies to further decipher the function of KIF2C in malignant tumor development and progression. This might help to establish KIF2C as a biomarker for the diagnosis or evaluation of at least three cancer entities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Standardized IETA criteria enhance accuracy of junior and intermediate ultrasound radiologists in diagnosing malignant endometrial and intrauterine lesions.
- Author
-
Chen, B., Wang, P., He, W., Yang, P., Kong, Z., Wang, D., Huang, L., Chen, X., Zheng, Y., Chen, Q., Xu, H., and Qi, J.
- Subjects
- *
DIAGNOSTIC ultrasonic imaging , *ENDOMETRIAL tumors , *TUMOR diagnosis , *PRENATAL diagnosis , *RADIOLOGISTS - Abstract
ABSTRACT Objectives Methods Results Conclusions To transform the standardized descriptions of the ultrasound characteristics of endometrial and intrauterine lesions devised by the International Endometrial Tumor Analysis (IETA) group into a practical scoring method and to investigate whether application of this method enhances the diagnostic accuracy of ultrasound radiologists with different levels of experience in detecting malignancy compared with subjective assessment.This was a retrospective study of 855 patients with endometrial and/or intrauterine lesions, who were divided into a training (n = 600) and a validation (n = 255) set. Ultrasound radiologists with varying levels of experience (expert, intermediate and junior) evaluated all lesions by subjective assessment and according to IETA rules. Using IETA rules, the experts identified signs of malignancy in the training set, assigned scores for each indicator and validated the scoring method in the validation set. The intermediate‐level and junior ultrasound radiologists reassessed the malignancy of the lesions using the IETA scoring method and compared their classifications with those made previously by subjective assessment. Postsurgical pathological evaluation was used as the reference standard.Using subjective assessment, the experts demonstrated the highest level of diagnostic accuracy, with a sensitivity of 85.0%, specificity of 94.3% and an area under the receiver‐operating‐characteristics curve (AUC) of 0.897. Applying the IETA scoring method (comprising eight ultrasound characteristics that contributed to the total score) with a threshold of > 25 points for the diagnosis of malignancy achieved a sensitivity of 84.7%, specificity of 94.7% and AUC of 0.9533 in the training set, with similar performance in the validation set, when performed by experts. Using the IETA scoring method, both junior and intermediate ultrasound radiologists showed improvement in sensitivity (from 55.5% to 74.8% and from 70.2% to 77.1%, respectively), specificity (from 88.4% to 91.5% and from 87.4% to 92.2%, respectively) and AUC (from 0.704 to 0.827 and from 0.793 to 0.841, respectively) for diagnosing malignant lesions.The IETA scoring method exhibits high diagnostic efficacy for malignant endometrial and intrauterine lesions. This method compensates for the lack of experience among junior and intermediate‐level ultrasound radiologists, enhancing their diagnostic skill to a level nearing that of experienced senior ultrasound radiologists. Further research is essential to validate the practicality of implementing this method and to confirm its clinical value. © 2024 International Society of Ultrasound in Obstetrics and Gynecology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Usefulness and limitations of intraoperative pathological diagnosis using frozen sections for spinal cord tumors.
- Author
-
Tanaka, Yuki, Hirano, Toru, Ohashi, Masayuki, Tashi, Hideki, Makino, Tatsuo, Minato, Keitaro, Kawashima, Hiroyuki, Kakita, Akiyoshi, Hasegawa, Kazuhiro, and Watanabe, Kei
- Subjects
- *
EXTRAMEDULLARY diseases , *POSTOPERATIVE care , *SPINAL cord , *TUMOR diagnosis , *ASTROCYTOMAS , *SPINAL cord tumors , *FROZEN tissue sections - Abstract
Intraoperative pathological diagnosis has a major influence on the intra- and postoperative management of spinal cord tumors. Thus, the aim of this study was to assess the reliability of intraoperative pathological diagnosis for spinal cord lesions by comparing it with the final pathological diagnosis and to determine its usefulness and limitations. Three-hundred and three consecutive patients (mean age, 53.9 years) with neoplastic spinal cord lesions who underwent initial surgery between 2000 and 2021 were included. The anatomical locations of the spinal cord tumors and the implementation rate of intraoperative pathological diagnosis in each tumor type were evaluated. As the primary outcome, we determined the concordance rates between the intraoperative pathological diagnosis and the final diagnosis. When the intraoperative pathological diagnosis and final diagnosis were the same, the diagnosis was defined as a "match." Otherwise, the diagnosis was defined as a "mismatch." The overall implementation rate of intraoperative pathological diagnosis was 53%, with implementation rates of 71%, 45%, 47%, and 50% for intramedullary, intradural extramedullary, extradural, and dumbbell tumors, respectively. The overall concordance rate was 87.6%, with concordance rates of 80%, 95%, 75%, and 90% for intramedullary, intradural extramedullary, extradural, and dumbbell tumors, respectively (p < 0.05). The diagnoses of ependymomas, low-grade astrocytomas, and high-grade astrocytomas was occasionally difficult among intramedullary tumors. Among intradural extramedullary tumors, differentiation between grade 1 meningioma and high-grade meningioma was difficult using intraoperative pathological diagnosis. Surgeons must recognize the lower accuracy of intraoperative pathological diagnosis for intramedullary and extradural lesions and make a final decision by considering the intraoperative gross findings, preoperative clinical course, and imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Delays between Uveal Melanoma Diagnosis and Treatment Increase the Risk of Metastatic Death.
- Author
-
Stålhammar, Gustav
- Subjects
- *
CILIARY body , *TUMOR diagnosis , *TREATMENT delay (Medicine) , *OPTIC disc , *MELANOMA diagnosis , *UVEA cancer - Abstract
To investigate if the interval between diagnosis and treatment of posterior uveal melanoma (UM) is associated with metastatic death. Retrospective, single-center cohort study. A total of 1145 patients consecutively diagnosed with posterior UM at St. Erik Eye Hospital, Stockholm, Sweden, from 2012 to 2022, with recorded dates of diagnosis and primary treatment. This cohort represents 81% of all diagnosed patients in Sweden during this period. Data on the interval between diagnosis and treatment were collected for all patients. Its prognostic importance was examined with univariate and multivariate competing risks regressions, and cumulative incidence analyses. Incidence of metastatic death (UM mortality) for patients with prompt (< 1 month from diagnosis) versus delayed treatment (≥ 1 month) and subdistribution hazard ratios (exp(β j)) for every additional 10-day delay in treatment. The mean interval between diagnosis and treatment was 34 days (SD, 56, range, 0–932). Patients treated promptly had larger tumors at diagnosis, but there were no differences in patient age, tumor distance to the optic disc, rates of ciliary body involvement (CBI) or extraocular extension (EXE), or symptom duration before diagnosis. Those who were treated more than 1 month after diagnosis had greater UM mortality in American Joint Committee on Cancer (AJCC) stage II and III. In stage I, UM mortality for delayed treatment was lower for the first 10 years, followed by a marked spike in the 11th year. In multivariate competing risks regressions of all 1145 patients with tumor diameter, thickness, CBI, and EXE as covariates, the risk for UM mortality increased with 1% for every additional 10-day delay in treatment (exp(β j) 1.01). Among 355 patients treated with enucleation, this delay was associated with UM mortality, independent of AJCC stage, cytomorphology, and level of immunohistochemical BAP-1 expression. Increasing time between diagnosis and treatment of UM is associated with a higher risk of metastatic death. These results challenge a central concept in the understanding of metastatic progression and may indicate the existence of late metastatic seeding. They also underscore the importance of prompt treatment. Validation in independent cohorts is recommended. The author(s) have no proprietary or commercial interest in any materials discussed in this article. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Patient management with Head and Neck tumors—A nationwide data collection in oral and maxillofacial surgery.
- Author
-
Pabst, Andreas, Zeller, Alexander-N., Goetze, Elisabeth, Hölzle, Frank, Hoffmann, Jürgen, Raguse, Jan Dirk, and Wermker, Kai
- Subjects
- *
ORAL surgery , *CANCER treatment , *MAXILLOFACIAL surgery , *TUMOR diagnosis , *PATIENTS' families , *ORAL surgeons - Abstract
Introduction: This study analyzed oncologic patient management from initial tumor diagnosis to tumor follow-up in oral and maxillofacial surgery (OMFS) in Germany. Material and methods: A dynamic online questionnaire with a total of 44 questions was used to generate general and specific data regarding oncologic patient management with head and neck malignancies, supportive care, and (pre-) rehabilitation from initial tumor diagnosis to tumor follow-up and head and neck cancer center (HNCC) structures in OMFS in Germany. The questionnaire was sent to 81 OMFS departments affiliated with the German-Austrian-Swiss Working Group for Tumors of the Jaw and Facial Region (DÖSAK) and the German Association of Oral and Maxillofacial Surgery (DGMKG). Data analysis was conducted descriptively. Results: Forty-eight OMFS departments participated (response rate 59.26%), of which 36/48 (75%) were certified HNCC. 28/34 (82.4%) reported subjective improvements in oncologic care, most often interdisciplinary collaboration (21/33, 63.64%) and clinic structure changes (21/34, 61.76%). Nearly all OMFS departments present patients in multidisciplinary tumor boards (45/46, 97.83%) and aim for osseous reconstruction post-tumor resection (43/44, 97.73%). Significant discrepancies regarding the frequency of masticatory-functional dental rehabilitation following osseous reconstruction were observed. Before oncologic therapy, patients are offered various supportive services, mostly psychotherapy and psycho-oncological support (24/26, 92.31%). Post-therapy, speech therapy (43/43, 100%), physiotherapy (40/43, 93.02%), lymphatic drainage, and follow-up rehabilitation (39/43, 90.7%, respectively) are most often offered. 17/43 (39.53%) have oncological nursing staff. 36/40 (90%) manage patients and side effects during adjuvant therapy, while 5/41 (12.2%) provide proprietary palliative care. 36/41 (87.8%) offer counseling to patients and families. Conclusion: Oncologic patient care in OMFS is highly standardized and potentially attributable to many certified HNCCs in Germany. Certain treatment aspects are handled differently, possibly due to institution-specific reasons. Clinical relevance: The high homogeneity in treatment protocols reflects the widespread high and comparable treatment quality of head and neck malignancies in OMFS in Germany. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Cytological features of diffuse and circumscribed gliomas.
- Author
-
Esteban‐Rodríguez, Isabel, López‐Muñoz, Samuel, Blasco‐Santana, Luis, Mejías‐Bielsa, Jaime, Gordillo, Carlos H., and Jiménez‐Heffernan, José A.
- Subjects
- *
ASTROCYTOMAS , *GLIOMAS , *GLIOBLASTOMA multiforme , *TUMOR diagnosis , *TUMORS - Abstract
The current World Health Organization classification of gliomas is based on morphological, genetic, and molecular parameters. In this review, we intend to present the most relevant cytological features of these tumours, with a particular focus on their analysis during intraoperative studies. Rapid diagnosis is required in this context, and at present it is not possible to evaluate the genetic or molecular profile of a tumour intraoperatively. New terminology and diagnostic parameters have been introduced, but the essence of intraoperative recognition remains the same. The main challenge in astrocytoma IDH‐mutant, grade 2 is recognising the tissue as neoplastic. Since glioma grades 3 and 4 are assigned based on histological and genetic variables that are not necessarily measurable on cytology, the term high‐grade glioma is often used for intraoperative diagnosis. Oligodendroglioma, IDH‐mutant and 1p/19q‐codeleted shows peculiar cytological findings as well as the common subtypes of glioblastoma IDH‐wildtype (giant cell, epithelioid, gliosarcoma and small cell). Many of the paediatric‐type‐diffuse gliomas have been described very recently and there are no cytological reports of proven cases. Finally, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, chordoid glioma, and astroblastoma MN1‐altered constitute the group of circumscribed astrocytic gliomas. They are remarkable entities that the pathologist must be able to recognise since most are low‐grade neoplasms that can show atypical morphological features. The last world health organization classification of gliomas is based on morphologic, genetic, and molecular parameters. The latter have modified considerably our understanding and diagnosis of these tumors. In this review we intend to show their most relevant cytologic features, and it is especially aimed at their analysis during intraoperative studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Comparison of the value of the GI-RADS and ADNEX models in the diagnosis of adnexal tumors by junior physicians.
- Author
-
Yongjian Chen, Yanru Li, Huiling Su, and Guorong Lyu
- Subjects
OVARIAN tumors ,RECEIVER operating characteristic curves ,PHYSICIANS ,BENIGN tumors ,TUMOR diagnosis ,OVARIAN cancer - Abstract
Objective: To compare the diagnostic effectiveness of the Gynecologic Imaging Reporting and Data System (GI-RADS) and Neoplasias in the Adnexa (ADNEX) model for the diagnosis of benign and malignant ovarian tumors by junior physicians. Methods: The sonographic data of 634 patients with ovarian tumors confirmed by pathology in our hospital over 4 years were analyzed retrospectively by junior doctors. The diagnostic efficacy of the GI-RADS and ADNEX models was compared based on pathology. Results: (1) Regarding the diagnostic efficacy of the GI-RADS and ADNEX models, the sensitivity was 90.15% and 84.85%, the specificity was 87.65% and 85.86%, the accuracy rates were 88.17% and 85.65%, and the Youden Indices were 0.778 and 0.707, respectively. The areas under the receiver operating characteristic (ROC) curves were 0.924 (95% CI: 0.900-0.943) and 0.933 (95% CI: 0.911-0.951), respectively. The GI-RADS classification was equivalent to that of the ADNEX model in the diagnosis of adnexal tumors (P>0.05). These findings were highly consistent with the pathological results (Kappa values were 0.684 and 0.691, respectively). (2) When differentiating between different pathological types of adnexal tumors, the ADNEX model had the best diagnostic value for distinguishing between benign tumors and stage II-IV ovarian cancer (AUC=0.990, 95% CI: 0.978-0.997). Conclusions: (1) The diagnostic efficacy of the GI-RADS and ADNEX models in the diagnosis of benign and malignant ovarian tumors by junior physicians is excellent and comparable. (2) The ADNEX model shows good value for differentiating ovarian tumors of different pathological types by junior physicians [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Hepatic perivascular epithelioid cell tumor: a retrospective analysis of 36 cases.
- Author
-
Min Ji, Yuchen Zhang, Shuaibing Liu, Menghui Zhang, and Bingbing Qiao
- Subjects
ABDOMINAL tumors ,CHEMOEMBOLIZATION ,CATHETER ablation ,TUMOR diagnosis ,CANCER relapse ,CELL tumors - Abstract
Background and aims: Hepatic perivascular epithelioid cell tumor (PEComa) is a rare type of mesenchymal neoplasm and lacks systematic reports. The aim was to analyze the features of hepatic PEComa in order to provide our own experience for diagnosis and management from a single center. Methods: We retrospectively analyzed clinical data, imaging findings, pathology, treatments and prognosis of 36 patients with hepatic PEComa in the First Affiliated Hospital of Zhengzhou University from January 2016 to September 2023. Results: 29 females and 7 males (median age, 47.8 years) were included in this study. The majority (26/36, 72.2%) of patients were diagnosed incidentally with non-specific symptoms. Abnormal enhancement of enlarged blood vessels (27/ 36,75%) can be observed on CT/MRI and only 7 patients (19.4%) were correctly diagnosed by imaging examinations. The positive immunohistochemical expressions were HMB-45(35/36,97.2%), Melan-A (34/35,97.1%), SMA (23/ 26,88.5%) and CD34(86.7%,26/30). Treatments include resection (24/36,67.7%), radiofrequency ablation (6/36,16.7%), transcatheter arterial chemoembolization (1/36,2.7%), conservative clinical follow-up(2/36,5.6%), and sirolimuschemotherapy (3/36,8.3%). During the follow-up period (range, 2–81 months), except for one patient with a single intrahepatic recurrence and 3 malignant patients died in 6 months, the remaining patients had no signs of recurrence and metastasis. Conclusions: Hepatic PEComa has no specific clinical features and mainly depends on clinicopathological characteristics for accurate diagnosis. Resection is the best treatment for benign PEComa, but TACE and radiofrequency ablation can also be considered in case of contraindications for surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. MicroRNA-98 as a novel diagnostic marker and therapeutic target in cancer patients.
- Author
-
Akhlaghipour, Iman and Moghbeli, Meysam
- Subjects
MOLECULAR biology ,TUMOR diagnosis ,DELAYED diagnosis ,CANCER invasiveness ,TUMOR markers - Abstract
The progress of cancer treatment methods in the last decade has significantly reduced mortality rate among these patients. Nevertheless, cancer is still recognized as one of the main causes of human deaths. One of the main reasons for the high death rate in cancer patients is the late diagnosis in the advanced tumor stages. Therefore, it is necessary to investigate the molecular biology of tumor progressions in order to introduce early diagnostic markers. MicroRNAs (miRNAs) have an important role in regulating cellular processes associated with tumor progression. Due to the high stability of miRNAs in body fluids, they are widely used as non-invasive markers in the early tumor diagnosis. Since, deregulation of miR-98 has been reported in a wide range of cancers, we investigated the molecular mechanisms of miR-98 during tumor progression. It has been reported that miR-98 mainly inhibits the tumor growth by the modulation of transcription factors and signaling pathways. Therefore, miR-98 can be introduced as a tumor marker and therapeutic target among cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. The role of superior hemorrhoidal vein ectasia in the preoperative staging of rectal cancer.
- Author
-
Maria Lucarelli, Nicola, Mirabile, Alessandra, Maggialetti, Nicola, Morelli, Chiara, Calbi, Roberto, Bartoli, Simona, Avella, Pasquale, Saccente, Domenico, Greco, Sara, and Ianora Stabile, Antonio Amato
- Subjects
COMPUTED tomography ,COLORECTAL cancer ,TUMOR diagnosis ,REFERENCE values ,CANCER diagnosis ,RECTAL cancer - Abstract
Objective: The prognosis of colorectal cancer has continuously improved in recent years thanks to continuous progress in both the therapeutic and diagnostic fields. The specific objective of this study is to contribute to the diagnostic field through the evaluation of the correlation between superior hemorrhoidal vein (SHV) ectasia detected on computed tomography (CT) and Tumor (T), Node (N), and distant metastasis (M) examination and mesorectal fascia (MRF) invasion in the preoperative staging of rectal cancer. Methods: Between January 2018 and April 2022, 46 patients with histopathological diagnosis of rectal cancer were retrospectively enrolled, and the diameter of the SHV was evaluated by CT examination. The cutoff value for SHV diameter used is 3.7 mm. The diameter was measured at the level of S2 during portal venous phase after 4× image zoom to reduce the interobserver variability. The parameters evaluated were tumor location, detection of MRF infiltration (defined as the distance < 1 mm between the tumor margins and the fascia), SHV diameter, detection of mesorectal perilesional lymph nodes, and detection of metastasis. Results: A total of 67.39% (31/46) of patients had SHV ectasia. All patients with MRF infiltration (4/46, 7.14%) presented SHV ectasia (average diameter of 4.4 mm), and SHV was significantly related with the development of liver metastases at the moment of primary staging and during follow-up. Conclusion: SHV ectasia may be related to metastasis and MRF involvement; therefore, it could become a tool for preoperative staging of rectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Medical management of post-sublobar resection pulmonary granulomatous lesion: a report of two cases.
- Author
-
Endoh, Hideki, Oura, Nariaki, Yanagisawa, Satoru, Morozumi, Nobutoshi, Nishizawa, Nobuhiro, Yamamoto, Ryohei, and Satoh, Yukitoshi
- Subjects
CHRONIC cough ,SUTURES ,COMPUTED tomography ,DISEASE relapse ,TUMOR diagnosis ,COUGH - Abstract
Background: Automatic stapling devices are commonly utilized in pulmonary resections, including sublobar segmentectomy. Large tumors can develop around the staple line, posing challenges in distinguishing them from cancer recurrence or inflammatory changes. In this report, we present two cases of symptomatic staple granulomatous lesion effectively managed with medications. Case presentation: A 74-year-old man presented with a persistent cough and sputum production six years post-segmentectomy for a hamartoma in the left upper lobe. Chest computed tomography (CT) revealed a large tumor around the staple line. Laboratory investigations and bronchoscopic examination revealed no malignancy. The patient received corticosteroids and a cyclooxygenase-2 inhibitor; despite experiencing adverse reactions to steroids, both tumor size and respiratory symptoms were significantly reduced. The second case involved a 78-year-old woman who underwent pulmonary resection for suspected lung cancer. Despite a non-malignant tumor diagnosis, she reported a cough six months post-surgery. Chest CT revealed extensive shadow around the surgical staple, which was diagnosed as mycobacterium granuloma. Low-dose erythromycin induced inflammatory changes but effectively reduced the lesion. Conclusions: Granulomatous lesions around the staple can be effectively managed with medication, and monitoring the treatment response proves valuable in distinguishing them from tumor recurrence post-pulmonary resection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Recurrent bladder urothelial carcinoma complicated with primary bladder large cell neuroendocrine carcinoma: a case report and literature review.
- Author
-
Jiarui Cui, Qing Zhao, Chunhong Yu, Pengfei Ma, and Shoubin Li
- Subjects
NEUROENDOCRINE tumors ,LITERATURE reviews ,NEUROENDOCRINE cells ,TRANSITIONAL cell carcinoma ,TUMOR diagnosis - Abstract
Objective: To improve the understanding, diagnosis and treatment of bladder large cell neuroendocrine carcinoma (LCNEC). Methods: A clinical case of bladder LCNEC admitted to our hospital was reported. The epidemiology, prognosis, diagnosis and treatment methods of large cell neuroendocrine carcinoma were reviewed. The diagnosis and treatment status and prognosis were discussed based on the literature. Results: The female patient was admitted to hospital for "more than 4 years after TURBT and intermittent hematuria for more than 2 years". She was diagnosed as recurrent bladder cancer and underwent "radical cystotomy + hysterectomy". The postoperative pathological findings were high-grade urothelial carcinoma of the bladder neck and large cell neuroendocrine carcinoma of the bladder. The patient recovered well after surgery, but refused radiotherapy and chemotherapy and is still under close follow-up. Conclusion: Bladder LCNEC is clinically rare, has unique pathological features, is more aggressive than traditional urothelial carcinoma, and has a poor prognosis. Surgery, chemotherapy and radiotherapy should be combined with multimode treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Real‐world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey.
- Author
-
Cheng, Li‐Jen, Kim, Janet, Mukherjee, Apurba, Milloy, Neil, Unsworth, Mia, and Ng, Daniel
- Subjects
- *
BRIEF Pain Inventory , *TRANSITIONAL cell carcinoma , *VISUAL analog scale , *BLADDER cancer , *TUMOR diagnosis - Abstract
Objectives: To evaluate demographic and clinical characteristics, treatment patterns, and quality of life in patients with locally advanced or metastatic urothelial carcinoma in Asia. Methods: Data were drawn from the Adelphi Real World Metastatic Urothelial Carcinoma Disease Specific Programme™, a cross‐sectional survey of medical oncologists/urologists and their adult patients in Saudi Arabia, South Korea, Taiwan, and Turkey. Exploratory patient‐reported outcomes included the EQ‐5D visual analog scale, European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health, and Brief Pain Inventory. Analyses were descriptive. Results: Overall, 175 physicians reported data for 988 patients. Mean (standard deviation) patient age was 66.3 (10.8) years, 77% were men, and 82% had bladder tumors at diagnosis. Of patients receiving first‐ (n = 988), second‐ (n = 290), and third‐line (n = 87) treatments, 81%, 35%, and 59% received chemotherapy, respectively, and 17%, 63%, and 34% received programmed cell death protein 1/ligand 1 inhibitors, respectively. Patient‐reported (n = 319) mean (standard deviation) EQ‐5D visual analog scale score was 51.8 (15.6), European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health status score was 44.6 (19.9), and Brief Pain Inventory score was 6.5 (1.9; n = 315). Conclusion: The most common first‐ and second‐line treatments for locally advanced or metastatic urothelial carcinoma were chemotherapy and programmed cell death protein 1/ligand inhibitors, respectively. At third line, 10% of patients received best supportive care alone, underscoring an unmet need for effective third‐line treatment options. Patients in all regions reported quality‐of‐life impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Assessing Knowledge, Counseling, and Referral Patterns Regarding Fertility Preservation Before Gonadotoxic Treatments Among Physicians in the Military Health System.
- Author
-
Boedeker, David, Hunkler, Kiley, Pekny, Carissa, Watson, Nora, Yamasaki, Meghan, Drayer, Sara, and Spitzer, Trimble
- Subjects
- *
TUMOR diagnosis , *MEDICAL protocols , *REPRODUCTIVE health , *OBSTETRICIANS , *CANCER patient medical care , *DESCRIPTIVE statistics , *CANCER patients , *PROFESSIONS , *CANCER chemotherapy , *PHYSICIAN practice patterns , *PHYSICIAN-patient relations , *PHYSICIANS , *FERTILITY preservation , *COUNSELING , *MILITARY medicine , *GYNECOLOGISTS , *ONCOLOGISTS , *MEDICAL referrals , *CANCER patient rehabilitation , *MILITARY hospitals - Abstract
Purpose: We sought to evaluate physicians' baseline knowledge of fertility preservation services available to patients with a cancer diagnosis within the military health system (MHS). Methods: Data on current cancer prevalence of over 31,000 unique cancer diagnoses were obtained from a comprehensive nationwide MHS dataset. Additionally, a 22-item survey was distributed to physicians practicing within the MHS assessing knowledge of reproductive health benefits, oncofertility counseling practices, and subspecialist referral patterns. Results: From 2020 to 2022, there were 31,103 individuals of reproductive age with cancer receiving care at a military treatment facility. One hundred fourteen physicians completed our survey, 76 obstetrician gynecologists (OB/GYNs), 18 oncologists, and 20 primary care physicians (PCPs). Ninety-three percent of respondents felt conversations about fertility preservation for reproductive-aged patients with cancer were very important. A total of 66.7% of oncologists, 35.5% of OB/GYNs, and 0% of PCPs felt comfortable counseling patients on coverage. A total of 33.3% of oncologists, 29.3% of OB/GYNs, and 0% of PCPs were familiar with oncofertility Defense Health Agency guidelines. Conclusion: Primary care, OB/GYN, and oncology practitioners are well situated to provide fertility preservation counseling to all individuals with a cancer diagnosis, but differences in counseling and referral patterns and a lack of knowledge of current agency policies may impair a patient's timely access to these resources. We propose implementation of an electronic patient navigator to address gaps in oncofertility care and standardize patient counseling in the MHS. This patient-focused guide would serve as a valuable model in all types of health care settings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Social Anxiety Symptoms in Adolescents and Young Adults Recently Diagnosed with Cancer.
- Author
-
Schilstra, Clarissa E., Sansom-Daly, Ursula M., Ellis, Sarah J., Anazodo, Antoinette C., Trahair, Toby N., Lindsay, Toni, Amiruddin, Azhani, O'Dwyer, Cath, Maguire, Fiona, Nevin, Suzanne, Battisti, Robert, and Fardell, Joanna E.
- Subjects
- *
TUMOR diagnosis , *RISK assessment , *TUMORS in children , *DISEASE duration , *PSYCHOLOGICAL distress , *DESCRIPTIVE statistics , *BODY image , *SOCIAL perception , *LONGITUDINAL method , *PERSONAL beauty , *RESEARCH methodology , *TUMORS , *SOCIODEMOGRAPHIC factors , *CANCER patient psychology , *SOCIAL support , *SOCIAL anxiety , *MENTAL depression , *WELL-being , *ADOLESCENCE , *ADULTS - Abstract
Purpose: Social anxiety disorder (SAD) remains an understudied potential link between the cancer experience and adolescent and young adult (AYA) cancer survivors' poor psychosocial outcomes. We investigated the frequency and duration of, as well as factors associated with, symptoms of SAD among AYAs with cancer. Methods: This longitudinal, mixed-methods study involved online surveys (including a validated screening tool for SAD) at recruitment and 6 months later, and a structured clinical interview. Results: Twenty-eight AYAs (aged 12–30 years, <1-year postdiagnosis, 50% male) completed the first survey (M = 6 months postdiagnosis). About 32% reported clinically significant SAD symptoms. Fourteen completed the follow-up survey (M = 12 months postdiagnosis), of which 9 (62%) reported persistent or worse symptoms of SAD significantly associated with emotional distress, physical appearance concerns, negative social cognitions, and depression. Conclusion: A subset of AYAs with cancer may experience clinically significant SAD symptoms that can affect their psychosocial well-being. Further work on how to best identify and support AYAs with SAD is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Tumor-derived extracellular vesicle proteins as new biomarkers and targets in precision oncology.
- Author
-
Liao, Haiyan, Zhang, Cheng, Wang, Fen, Jin, Feng, Zhao, Qiqi, Wang, Xinying, Wang, Shubin, and Gao, Jing
- Subjects
- *
EXTRACELLULAR vesicles , *BIOMARKERS , *TUMOR microenvironment , *NON-coding RNA , *PROTEINS - Abstract
Extracellular vesicles (EVs) are important carriers of signaling molecules, such as nucleic acids, proteins, and lipids, and have become a focus of increasing interest due to their numerous physiological and pathological functions. For a long time, most studies on EV components focused on noncoding RNAs; however, in recent years, extracellular vesicle proteins (EVPs) have been found to play important roles in diagnosis, treatment, and drug resistance and thus have been considered favorable biomarkers and therapeutic targets for various tumors. In this review, we describe the general protocols of research on EVPs and summarize their multifaceted roles in precision medicine applications, including cancer diagnosis, dynamic monitoring of therapeutic efficacy, drug resistance research, tumor microenvironment interaction research, and anticancer drug delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. An Overview of Cancer Biology, Pathophysiological Development and It's Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy.
- Author
-
Al-Ostoot, Fares Hezam, Salah, Salma, and Khanum, Shaukath Ara
- Subjects
- *
TUMOR treatment , *TUMOR risk factors , *TUMOR diagnosis , *TUMOR classification , *RISK assessment , *CELL physiology , *APOPTOSIS , *IMMUNOTHERAPY , *CELLULAR signal transduction , *NEOVASCULARIZATION inhibitors , *CELL lines , *METASTASIS , *TUMORS , *PATHOLOGIC neovascularization , *DISEASE progression , *SYMPTOMS - Abstract
A number of conditions and factors can cause the transformation of normal cells in the body into malignant tissue by changing the normal functions of a wide range of regulatory, apoptotic, and signal transduction pathways. Despite the current deficiency in fully understanding the mechanism of cancer action accurately and clearly, numerous genes and proteins that are causally involved in the initiation, progression, and metastasis of cancer have been identified. But due to the lack of space and the abundance of details on this complex topic, we have emphasized here more recent advances in our understanding of the principles implied tumor cell transformation, development, invasion, angiogenesis, and metastasis. Inhibition of angiogenesis is a significant strategy for the treatment of various solid tumors, that essentially depend on cutting or at least limiting the supply of blood to micro-regions of tumors, leading to pan-hypoxia and pan-necrosis inside solid tumor tissues. Researchers have continued to enhance the efficiency of anti-angiogenic drugs over the past two decades, to identify their potential in the drug interaction, and to discover reasonable interpretations for possible resistance to treatment. In this review, we have discussed an overview of cancer history and recent methods use in cancer therapy, focusing on anti-angiogenic inhibitors targeting angiogenesis formation. Further, this review has explained the molecular mechanism of action of these anti-angiogenic inhibitors in various tumor types and their limitations use. In addition, we described the synergistic mechanisms of immunotherapy and anti-angiogenic therapy and summarizes current clinical trials of these combinations. Many phase III trials found that combining immunotherapy and anti-angiogenic therapy improved survival. Therefore, targeting the source supply of cancer cells to grow and spread with new anti-angiogenic agents in combination with different conventional therapy is a novel method to reduce cancer progression. The aim of this paper is to overview the varying concepts of cancer focusing on mechanisms involved in tumor angiogenesis and provide an overview of the recent trends in anti-angiogenic strategies for cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Exploring the Dark Matter of Human Proteome: The Emerging Role of Non-Canonical Open Reading Frame (ncORF) in Cancer Diagnosis, Biology, and Therapy.
- Author
-
Ge, Anni, Chan, Curtis, and Yang, Xiaolong
- Subjects
- *
TUMOR treatment , *RNA metabolism , *TUMOR diagnosis , *PROTEIN metabolism , *HEALTH literacy , *EPITHELIAL cells , *GENOMICS , *PROTEIN kinases , *IMMUNE system , *CANCER cell culture , *PEPTIDES , *BIOINFORMATICS , *PROTEOMICS , *ONCOGENES , *TUMORS - Abstract
Simple Summary: With advanced bioinformatic and sequencing technologies, many non-coding RNAs have been found to harbor non-canonical open reading frames (ncORFs). Some studies suggest that many ncORF-encoded microproteins or micropeptides possess important roles in cancer biology, yet the functional roles of these ncORF-encoded peptides are mostly unknown. The purpose of this review is to provide a comprehensive overview of existing knowledge on ncORF-encoded microproteins in cancer biology and highlight their roles as potential prognostic and therapeutic targets in cancer. Cancer develops from abnormal cell growth in the body, causing significant mortalities every year. To date, potent therapeutic approaches have been developed to eradicate tumor cells, but intolerable toxicity and drug resistance can occur in treated patients, limiting the efficiency of existing treatment strategies. Therefore, searching for novel genes critical for cancer progression and therapeutic response is urgently needed for successful cancer therapy. Recent advances in bioinformatics and proteomic techniques have allowed the identification of a novel category of peptides encoded by non-canonical open reading frames (ncORFs) from historically non-coding genomic regions. Surprisingly, many ncORFs express functional microproteins that play a vital role in human cancers. In this review, we provide a comprehensive description of different ncORF types with coding capacity and technological methods in discovering ncORFs among human genomes. We also summarize the carcinogenic role of ncORFs such as pTINCR and HOXB-AS3 in regulating hallmarks of cancer, as well as the roles of ncORFs such as HOXB-AS3 and CIP2A-BP in cancer diagnosis and prognosis. We also discuss how ncORFs such as AKT-174aa and DDUP are involved in anti-cancer drug response and the underestimated potential of ncORFs as therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Clinical impact of CEUS on non-characterizable observations and observations with intermediate probability of malignancy on CT/MRI in patients at risk for HCC.
- Author
-
Kono, Yuko, Piscaglia, F., Wilson, S. R., Medellin, A., Rodgers, S. K., Planz, V., Kamaya, A., Fetzer, D. T., Berzigotti, A., Sidhu, P. S., Wessner, C. E., Bradigan, K., Kuon Yeng Escalante, Cristina M., Siu Xiao, T., Eisenbrey, J. R., Forsberg, F., Lyshchik, A., Yusuf, Gibran T., Suddle, Abid, and Rafailidis, Vasileios D.
- Subjects
- *
ULTRASOUND contrast media , *MAGNETIC resonance imaging , *CONTRAST-enhanced ultrasound , *TUMOR diagnosis , *COMPUTED tomography - Abstract
Background: Hepatocellular carcinoma (HCC) is a unique cancer allowing tumor diagnosis with identification of definitive patterns of enhancement on contrast-enhanced imaging, avoiding invasive biopsy. However, it is still unclear to what extent Contrast-Enhanced Ultrasound (CEUS) is a clinically useful additional step when Computed tomography (CT) or Magnetic resonance imaging (MRI) are inconclusive. Methods: A prospective international multicenter validation study for CEUS Liver Imaging Reporting and Data System (LI-RADS) was conducted between January 2018 and August 2021. 646 patients at risk for HCC with focal liver lesions were enrolled. CEUS was performed using an intravenous ultrasound contrast agent within 4 weeks of CT/MRI. Liver nodules were categorized based on LI-RADS (LR) criteria. Histology or one-year follow-up CT/MRI imaging results were used as the reference standard. The diagnostic performance of CEUS was evaluated for inconclusive CT/MRI scan in two scenarios for which the AASLD recommends repeat imaging or imaging follow-up: observations deemed non-characterizable (LR-NC) or with indeterminate probability of malignancy (LR-3). Results: 75 observations on CT or MRI were categorized as LR-3 (n = 54) or LR-NC (n = 21) CEUS recategorization of such observations into a different LR category (namely, into one among LR-1, LR-2, LR-5, LR-M, or LR-TIV) resulted in management recommendation changes in 33.3% (25/75) and in all but one (96.0%, 24/25) observation, the new management recommendations were correct. Conclusion: CEUS LI-RADS resulted in management recommendations change in substantial number of liver observations with initial indeterminate CT/MRI characterization, identifying both non-malignant lesions and HCC, potentially accelerating the diagnostic process and alleviating the need for biopsy or follow-up imaging. ClinicalTrials.gov number, NCT03318380. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Emerging Head and Neck Tumor Targeting Contrast Agents for the Purpose of CT, MRI, and Multimodal Diagnostic Imaging: A Molecular Review.
- Author
-
Neilio, Jonathan M. and Ginat, Daniel T.
- Subjects
- *
CONTRAST media , *NECK tumors , *HEAD tumors , *TUMOR diagnosis , *DIAGNOSTIC imaging , *HEAD & neck cancer - Abstract
Background. The diagnosis and treatment of head and neck tumors present significant challenges due to their infiltrative nature and diagnostic hindrances such as the blood–brain barrier. The intricate anatomy of the head and neck region also complicates the clear identification of tumor boundaries and assessment of tumor characteristics. Aim. This review aims to explore the efficacy of molecular imaging techniques that employ targeted contrast agents in head and neck cancer imaging. Head and neck cancer imaging benefits significantly from the combined advantages of CT and MRI. CT excels in providing swift, high-contrast images, enabling the accurate localization of tumors, while MRI offers superior soft tissue resolution, contributing to the detailed evaluation of tumor morphology in this region of the body. Many of these novel contrast agents have integration of dual-modal, triple-modal, or even dual-tissue targeting imaging, which have expanded the horizons of molecular imaging. Emerging contrast agents for the purpose of MRI and CT also include the widely used standards in imaging such as gadolinium and iodine-based agents, respectively, but with peptide, polypeptide, or polymeric functionalizations. Relevance for patients. For patients, the development and use of these targeted contrast agents have potentially significant implications. They benefit from the enhanced accuracy of tumor detection and characterization, which are critical for effective treatment planning. Additionally, these agents offer improved imaging contrast with the added benefit of reduced toxicity and bioaccumulation. The summarization of preclinical nanoparticle research in this review serves as a valuable resource for scientists and students working towards advancing tumor diagnosis and treatment with targeted contrast agents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. An automated approach for real-time informative frames classification in laryngeal endoscopy using deep learning.
- Author
-
Baldini, Chiara, Azam, Muhammad Adeel, Sampieri, Claudio, Ioppi, Alessandro, Ruiz-Sevilla, Laura, Vilaseca, Isabel, Alegre, Berta, Tirrito, Alessandro, Pennacchi, Alessia, Peretti, Giorgio, Moccia, Sara, and Mattos, Leonardo S.
- Subjects
- *
DEEP learning , *ARTIFICIAL intelligence , *ENDOSCOPY , *TUMOR diagnosis , *DATA warehousing , *CONCEPT learning , *SCHOOL entrance requirements , *ADRENAL insufficiency - Abstract
Purpose: Informative image selection in laryngoscopy has the potential for improving automatic data extraction alone, for selective data storage and a faster review process, or in combination with other artificial intelligence (AI) detection or diagnosis models. This paper aims to demonstrate the feasibility of AI in providing automatic informative laryngoscopy frame selection also capable of working in real-time providing visual feedback to guide the otolaryngologist during the examination. Methods: Several deep learning models were trained and tested on an internal dataset (n = 5147 images) and then tested on an external test set (n = 646 images) composed of both white light and narrow band images. Four videos were used to assess the real-time performance of the best-performing model. Results: ResNet-50, pre-trained with the pretext strategy, reached a precision = 95% vs. 97%, recall = 97% vs, 89%, and the F1-score = 96% vs. 93% on the internal and external test set respectively (p = 0.062). The four testing videos are provided in the supplemental materials. Conclusion: The deep learning model demonstrated excellent performance in identifying diagnostically relevant frames within laryngoscopic videos. With its solid accuracy and real-time capabilities, the system is promising for its development in a clinical setting, either autonomously for objective quality control or in conjunction with other algorithms within a comprehensive AI toolset aimed at enhancing tumor detection and diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Caseous mitral annulus calcification: A forgotten benign condition mimicking cardiac mass, a case report.
- Author
-
Nèji, Henda, Bennour, Emna, Baccouche, Ines, Kechaou, Salma, Kammoun, Ikram, Affes, Meriem, and Hantous‐Zannad, Saoussen
- Subjects
- *
MAGNETIC resonance imaging , *CARDIAC magnetic resonance imaging , *COMPUTED tomography , *TUMOR diagnosis , *MITRAL valve - Abstract
Key Clinical Message: Caseous mitral annulus calcification is a rare benign condition that can be misdiagnosed on echocardiography especially when it presents as a mass. This report highlights the contribution of cardiac MRI and computed tomography to the diagnosis through the case of a patient previously treated for breast cancer. We report the case of a patient, previously treated for breast cancer, in whom echocardiography suggested the diagnosis of a cardiac tumor due the presence of a mass on the posterior mitral annulus. Cardiac magnetic resonance was inconclusive. Computed tomography confirmed the diagnosis of caseous mitral annulus calcification. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. DNA nanosensor based on bipedal 3D DNA walker–driven proximal catalytic hairpin assembly for sensitive and fast TK1 mRNA detection.
- Author
-
Gong, Hang, Yao, Shufen, Zhao, Xiaojia, Chen, Feng, Chen, Chunyan, and Cai, Changqun
- Subjects
- *
CHEMICAL kinetics , *HAIRPIN (Genetics) , *BIPEDALISM , *MAGNETIC nanoparticles , *TUMOR diagnosis - Abstract
Hyperproliferative diseases are the first step for tumor formation; thymidine kinase 1 (TK1) mRNA is closely related to cell proliferation. Therefore, the risk of malignant proliferation can be identified by sensitively detecting the variance in TK1 mRNA concentration, which can be used for tumor auxiliary diagnosis and monitoring tumor treatment. Owing to the low abundance and instability of TK1 mRNA in real samples, the development of a sensitive and fast mRNA detection method is necessary. A DNA nanosensor that can be used for detecting TK1 mRNA based on bipedal 3D DNA walker–driven proximal catalytic hairpin assembly (P-CHA) was developed. P-CHA hairpins were hybridized to a linker DNA strand coupled with magnetic nanoparticles to increase their local concentrations. The bipedal DNA walking on the surface of NPs accelerates reaction kinetics using the proximity effect. Taking advantage of the signal amplification of P-CHA as well as the rapid reaction rate of the DNA walker in 80 min, the proposed sensor detects TK1 mRNA with a low detection limit of 14 pM and may then be applied to clinical diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Radiomics in differential diagnosis of Wilms tumor and neuroblastoma with adrenal location in children.
- Author
-
Koska, Ilker Ozgur, Ozcan, H. Nursun, Tan, Aziz Anil, Beydogan, Beyza, Ozer, Gozde, Oguz, Berna, and Haliloglu, Mithat
- Subjects
- *
NEPHROBLASTOMA , *RADIOMICS , *NEUROBLASTOMA , *ADRENAL tumors , *TUMOR diagnosis , *DIFFERENTIAL diagnosis - Abstract
Objectives: Machine learning methods can be applied successfully to various medical imaging tasks. Our aim with this study was to build a robust classifier using radiomics and clinical data for preoperative diagnosis of Wilms tumor (WT) or neuroblastoma (NB) in pediatric abdominal CT. Material and methods: This is a single-center retrospective study approved by the Institutional Ethical Board. CT scans of consecutive patients diagnosed with WT or NB admitted to our hospital from January 2005 to December 2021 were evaluated. Three distinct datasets based on clinical centers and CT machines were curated. Robust, non-redundant, high variance, and relevant radiomics features were selected using data science methods. Clinically relevant variables were integrated into the final model. Dice score for similarity of tumor ROI, Cohen's kappa for interobserver agreement among observers, and AUC for model selection were used. Results: A total of 147 patients, including 90 WT (mean age 34.78 SD: 22.06 months; 43 male) and 57 NB (mean age 23.77 SD:22.56 months; 31 male), were analyzed. After binarization at 24 months cut-off, there was no statistically significant difference between the two groups for age (p =.07) and gender (p =.54). CT clinic radiomics combined model achieved an F1 score of 0.94, 0.93 accuracy, and an AUC 0.96. Conclusion: In conclusion, the CT-based clinic-radiologic-radiomics combined model could noninvasively predict WT or NB preoperatively. Notably, that model correctly predicted two patients, which none of the radiologists could correctly predict. This model may serve as a noninvasive preoperative predictor of NB/WT differentiation in CT, which should be further validated in large prospective models. Clinical relevance statement: CT-based clinic-radiologic-radiomics combined model could noninvasively predict Wilms tumor or neuroblastoma preoperatively. Key Points: • CT radiomics features can predict Wilms tumor or neuroblastoma from abdominal CT preoperatively. • Integrating clinic variables may further improve the performance of the model. • The performance of the combined model is equal to or greater than human readers, depending on the lesion size. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Radiomics for clinical decision support in radiation oncology.
- Author
-
Russo, L., Charles-Davies, D., Bottazzi, S., Sala, E., and Boldrini, L.
- Subjects
- *
TUMOR diagnosis , *RADIOTHERAPY , *MEDICAL quality control , *RADIOMICS , *CLINICAL decision support systems , *CANCER patient medical care , *RADIATION injuries , *ONCOLOGY , *DECISION making in clinical medicine , *TUMOR markers , *RADIATION dosimetry , *TUMORS , *RADIATION doses - Abstract
Radiomics is a promising tool for the development of quantitative biomarkers to support clinical decision-making. It has been shown to improve the prediction of response to treatment and outcome in different settings, particularly in the field of radiation oncology by optimising the dose delivery solutions and reducing the rate of radiation-induced side effects, leading to a fully personalised approach. Despite the promising results offered by radiomics at each of these stages, standardised methodologies, reproducibility and interpretability of results are still lacking, limiting the potential clinical impact of these tools. In this review, we briefly describe the principles of radiomics and the most relevant applications of radiomics at each stage of cancer management in the framework of radiation oncology. Furthermore, the integration of radiomics into clinical decision support systems is analysed, defining the challenges and offering possible solutions for translating radiomics into a clinically applicable tool. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Intraoperative Imaging Techniques in Oncology.
- Author
-
Vulasala, S.S., Sutphin, P., Shyn, P., and Kalva, S.
- Subjects
- *
TUMOR treatment , *HEAD & neck cancer diagnosis , *TUMOR diagnosis , *PREVENTIVE medicine , *SHEAR (Mechanics) , *BIOPSY , *DIAGNOSTIC imaging , *SURGICAL therapeutics , *ULTRASONIC imaging , *POSITRON emission tomography computed tomography , *MAGNETIC resonance imaging , *TUMORS ,TUMOR surgery - Abstract
Imaging-based procedures have become well integrated into the diagnosis and management of oncological patients and play a significant role in reducing morbidity and mortality rates. Here we describe the established and upcoming surgical oncological imaging techniques and their impact on cancer management. • Shear wave elastography allows the selective biopsy of tissue and avoids the regions with a high procedural bleeding risk. • PET/CT allows the selective sampling of active lymphomatous tissue by visualizing high fluorodeoxyglucose avidity. • Intraoperative MRI offers high resolution anatomy and aids in head and neck biopsies without causing neurovascular damage. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Imaging Analytics using Artificial Intelligence in Oncology: A Comprehensive Review.
- Author
-
Chakrabarty, N. and Mahajan, A.
- Subjects
- *
TUMOR diagnosis , *RISK assessment , *COST control , *ARTIFICIAL intelligence , *CANCER patient medical care , *RADIOMICS , *EARLY detection of cancer , *TREATMENT effectiveness , *DEEP learning , *COMPUTER-aided diagnosis , *GENETIC mutation , *TUMORS , *ALGORITHMS - Abstract
The present era has seen a surge in artificial intelligence-related research in oncology, mainly using deep learning, because of powerful computer hardware, improved algorithms and the availability of large amounts of data from open-source domains and the use of transfer learning. Here we discuss the multifaceted role of deep learning in cancer care, ranging from risk stratification, the screening and diagnosis of cancer, to the prediction of genomic mutations, treatment response and survival outcome prediction, through the use of convolutional neural networks. Another role of artificial intelligence is in the generation of automated radiology reports, which is a boon in high-volume centres to minimise report turnaround time. Although a validated and deployable deep-learning model for clinical use is still in its infancy, there is ongoing research to overcome the barriers for its universal implementation and we also delve into this aspect. We also briefly describe the role of radiomics in oncoimaging. Artificial intelligence can provide answers pertaining to cancer management at baseline imaging, saving cost and time. Imaging biobanks, which are repositories of anonymised images, are also briefly described. We also discuss the commercialisation and ethical issues pertaining to artificial intelligence. The latest generation generalist artificial intelligence model is also briefly described at the end of the article. We believe this article will not only enrich knowledge, but also promote research acumen in the minds of readers to take oncoimaging to another level using artificial intelligence and also work towards clinical translation of such research. • Risk prediction using artificial intelligence can triage patients for cancer screening. • Artificial intelligence-based diagnosis and molecular mutation prediction can save cost and time. • Artificial intelligence-based treatment response and toxicity prediction can guide management decisions. • Artificial intelligence-based survival outcome and recurrence prediction can aid in prognostication. • Researchers to focus on clinical translation of the developed mathematical algorithm. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. A "Transformers"‐like nanochain for precise navigation and efficient cancer treatment.
- Author
-
Tian, Sichao, Zeng, Qian, Hu, Zhanglu, Zhang, Weidong, Ao, Zhuo, Han, Dong, and Xu, Qing‐Hua
- Subjects
CANCER treatment ,ACOUSTIC imaging ,PHOTOTHERMAL conversion ,TUMOR diagnosis ,TUMOR microenvironment ,NANOSATELLITES ,PHOTOACOUSTIC spectroscopy ,PHOTOACOUSTIC effect - Abstract
Integrated multimodal imaging in theranostics nanomaterials offers extensive prospects for precise and noninvasive cancer treatment. Precisely controlling the structural evolution of plasmonic nanoparticles is crucial in the development of photothermal agents. However, previous successes have been limited to static assemblies and single‐component structures. Here, an activatable plasmonic theranostics system utilizing self‐assembled 1D silver‐coated gold nanochains (1D nanochains) is presented for precise tumor diagnosis and effective treatment. The absorbance of the adaptable core–shell chain structure can shift from visible to near‐infrared (NIR) regions due to the fusion between nearby Au@Ag nanoparticles induced by elevated H2O2 levels in the tumor microenvironment (TME), resulting in the creation of a novel 3D aggregates with strong NIR absorption. With a high photothermal conversion efficiency of 60.2% at 808 nm, nanochains utilizing the TME‐activated characteristics show remarkable qualities for photoacoustic imaging and significantly limit tumor growth in vivo. This study may pave the way for precise tumor diagnosis and treatment through customizable, optically tunable adaptive plasmonic nanostructures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Pioneering cytopathology: Transformative insights into precision medicine, targeted immunotherapy, and planetary health advocacy.
- Author
-
Islam, Shahid and Matthew, Elizabeth
- Subjects
TUMOR treatment ,TUMOR diagnosis ,CYTOLOGY ,ENVIRONMENTAL health ,ECOLOGICAL impact ,IMMUNOTHERAPY ,MINIMALLY invasive procedures ,MEDICAL waste disposal ,SUSTAINABILITY ,NEEDLE biopsy ,INDIVIDUALIZED medicine ,GREENHOUSE gases ,MEDICAL care costs ,MOLECULAR pathology ,BIOMARKERS - Abstract
Copyright of Canadian Journal of Pathology is the property of Canadian Association of Pathologists and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
34. Endoscopic ultrasound-guided bite-on-bite biopsy and endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of gastric tumors with negative malignant endoscopy biopsies: a retrospective cohort study.
- Author
-
Min, Liang, Jin, Yan, Chen, Jiefei, Zhu, Hongyi, Liang, Chengbai, Lv, Liang, Wang, Yongjun, Liu, Deliang, Zhou, Yuqian, Chu, Yi, and Tan, Yuyong
- Subjects
- *
NEEDLE biopsy , *GASTRIC outlet obstruction , *TUMOR diagnosis , *ENDOSCOPIC ultrasonography , *BIOPSY , *COHORT analysis - Abstract
AbstractBackgroundMethodsResultsConclusionsSpecific types of gastric tumors, including gastric linitis plastica and lymphoma, may cause extensive deep-layer infiltration, impeding an accurate diagnosis with endoscopic biopsy. This study aims to evaluate the efficacy of endoscopic ultrasound (EUS)-guided bite-on-bite biopsy and EUS-guided fine-needle aspiration (EUS-FNA) in diagnosing gastric malignancies with negative endoscopic biopsies.We retrospectively analyzed suspicious malignant gastric lesion cases in our hospital from October 2017 to August 2023. Clinical manifestations, radiographical examinations, endoscopic examinations, histopathological results, and therapeutic strategies were recorded and analyzed.Forty malignant gastric tumor cases with negative endoscopic biopsies were incorporated into our study. EUS-guided bite-on-bite biopsy was performed in 16 cases exclusively, whereas 17 patients received EUS-FNA exclusively, and seven patients underwent both simultaneously. Among the 23 patients who received the EUS-guided bite-on-bite biopsy, 22 (95.7%) were diagnosed with malignancies. Among the 24 patients who received EUS-FNA, a total of 19 cases with malignancies (79.2%) were confirmed by EUS-FNA (
p = 0.11): 13 gastric adenocarcinomas, five metastatic malignancies, and one malignant stromal tumor. No adverse events were observed in any of the cases.EUS-guided bite-on-bite biopsy and EUS-FNA possess their advantages and disadvantages. EUS-guided bite-on-bite biopsy could serve as a reliable diagnostic method for shallow lesions with negative malignant endoscopic biopsies. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
35. A PET‐Surrogate Signature for the Interrogation of the Metabolic Status of Breast Cancers.
- Author
-
Confalonieri, Stefano, Matoskova, Bronislava, Pennisi, Rosa, Martino, Flavia, De Mario, Agnese, Miloro, Giorgia, Montani, Francesca, Rotta, Luca, Ferrari, Mahila Esmeralda, Gilardi, Laura, Ceci, Francesco, Grana, Chiara Maria, Rizzuto, Rosario, Mammucari, Cristina, Di Fiore, Pier Paolo, and Lanzetti, Letizia
- Subjects
- *
BREAST cancer , *FATTY acid oxidation , *BREAST , *TREATMENT effectiveness , *TUMOR diagnosis - Abstract
Metabolic alterations in cancers can be exploited for diagnostic, prognostic, and therapeutic purposes. This is exemplified by 18F‐fluorodeoxyglucose (FDG)‐positron emission tomography (FDG‐PET), an imaging tool that relies on enhanced glucose uptake by tumors for diagnosis and staging. By performing transcriptomic analysis of breast cancer (BC) samples from patients stratified by FDG‐PET, a 54‐gene signature (PETsign) is identified that recapitulates FDG uptake. PETsign is independently prognostic of clinical outcome in luminal BCs, the most common and heterogeneous BC molecular subtype, which requires improved stratification criteria to guide therapeutic decision‐making. The prognostic power of PETsign is stable across independent BC cohorts and disease stages including the earliest BC stage, arguing that PETsign is an ab initio metabolic signature. Transcriptomic and metabolomic analysis of BC cells reveals that PETsign predicts enhanced glycolytic dependence and reduced reliance on fatty acid oxidation. Moreover, coamplification of PETsign genes occurs frequently in BC arguing for their causal role in pathogenesis. CXCL8 and EGFR signaling pathways feature strongly in PETsign, and their activation in BC cells causes a shift toward a glycolytic phenotype. Thus, PETsign serves as a molecular surrogate for FDG‐PET that could inform clinical management strategies for BC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Innovative Imaging Techniques for Advancing Cancer Diagnosis and Treatment.
- Author
-
Wang, Tianyuan, Ni, Yicheng, and Liu, Li
- Subjects
- *
TUMOR treatment , *TUMOR diagnosis , *BIOPSY , *DIAGNOSTIC imaging , *PREDICTION models , *EARLY detection of cancer , *CLINICAL decision support systems , *ARTIFICIAL intelligence , *RADIOMICS , *TUMOR markers , *DEEP learning , *TUMORS - Published
- 2024
- Full Text
- View/download PDF
37. Correlation between microvascular density and perfusion parameters derived from dynamic contrast-enhanced computed tomography in dogs with tumors of the head.
- Author
-
Mortier, Jeremy R., Richards-Rios, Peter, Ressel, Lorenzo, and Busoni, Valeria
- Subjects
EPITHELIAL tumors ,DOG diseases ,COMPUTED tomography ,TUMOR diagnosis ,BLOOD vessels - Abstract
Background: Non-resectable tumors of the head can represent a therapeutic challenge in dogs and prognostic indicators and markers of response to treatment are needed. Tumor microenvironment, in particular microvascular density (MVD), affects response to treatment and prognosis. Methods: Perfusion parameters obtained from dynamic contrast-enhanced computed tomography (DCECT) have been correlated to MVD and outcome in humans. Twenty-five dogs comprising 16 epithelial tumors and 9 mesenchymal tumors of the head were prospectively recruited and underwent DCECT. Microvascular density (anti-Factor VIII) was assessed using a trained object classifier in stroma and tumor tissue. Results: Mesenchymal tumors had significantly higher percentage area of blood vessels in tumor tissue than epithelial tumors (P =.04). There was no significant association between perfusion parameters and MVD measurements. Conclusions: These findings suggest that mesenchymal tumors have a higher MVD than epithelial tumors, and that perfusion parameters derived from DCECT might not be well correlated with MVD in dogs with tumors of the head. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Chemiluminescent Afterglow Material for Enhanced Tumor Diagnosis and Photodynamic Therapy.
- Author
-
Huang, Shuai, Bai, Shuaige, Luo, Ting, Zheng, Fan, Fan, Duoyang, Zhou, Yiyang, Dong, Jie, Chen, Fei, and Zeng, Wenbin
- Subjects
- *
PHOTODYNAMIC therapy , *TUMOR diagnosis , *FLUORESCENCE resonance energy transfer , *REACTIVE oxygen species , *TUMOR growth , *LUMINESCENCE - Abstract
Afterglow materials offer great advantages for imaging, including
ultra‐long luminescent lifetimes for sustained signal after excitation,high signal‐to‐noise ratios due to minimal tissue autofluorescence interference, and the ability to achievedeep tissue penetration with near‐infrared (NIR) afterglow. AIEgens, known for theirpotent singlet oxygen (¹O₂) generation during photodynamic therapy (PDT), further enhance the approach. Here is the first report on how to integrate AIEgens with chemiluminescent agents for constructing NIR afterglow materials, enabling chemiluminescence resonance energy transfer (CRET)‐mediated activation of AIEgens for targeted PDT.DCL /TBQ nanoparticles (NPs) exemplify this promising theranostic design. These NPs exhibit high selectivity and sensitivity toward ONOO−, a biomarker associated with tumors, with a low limit of detection (46.1 nm). Additionally,DCL /TBQ NPs boast impressive deep tissue penetration (2 cm) and a remarkable 120‐fold improvement in signal‐to‐noise ratio for tumor afterglow imaging. Most importantly, significant tumor growth inhibition capabilities are demonstrated. This approach holds immense potential for the development of next‐generation theranostic agents, enabling simultaneous tumor diagnosis and treatment with improved accuracy and efficacy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
39. MR–CT image fusion method of intracranial tumors based on Res2Net.
- Author
-
Chen, Wei, Li, Qixuan, Zhang, Heng, Sun, Kangkang, Sun, Wei, Jiao, Zhuqing, and Ni, Xinye
- Subjects
IMAGE fusion ,INTRACRANIAL tumors ,MAGNETIC resonance imaging ,COMPUTED tomography ,TUMOR diagnosis - Abstract
Background: Information complementarity can be achieved by fusing MR and CT images, and fusion images have abundant soft tissue and bone information, facilitating accurate auxiliary diagnosis and tumor target delineation. Purpose: The purpose of this study was to construct high-quality fusion images based on the MR and CT images of intracranial tumors by using the Residual-Residual Network (Res2Net) method. Methods: This paper proposes an MR and CT image fusion method based on Res2Net. The method comprises three components: feature extractor, fusion layer, and reconstructor. The feature extractor utilizes the Res2Net framework to extract multiscale features from source images. The fusion layer incorporates a fusion strategy based on spatial mean attention, adaptively adjusting fusion weights for feature maps at each position to preserve fine details from the source images. Finally, fused features are input into the feature reconstructor to reconstruct a fused image. Results: Qualitative results indicate that the proposed fusion method exhibits clear boundary contours and accurate localization of tumor regions. Quantitative results show that the method achieves average gradient, spatial frequency, entropy, and visual information fidelity for fusion metrics of 4.6771, 13.2055, 1.8663, and 0.5176, respectively. Comprehensive experimental results demonstrate that the proposed method preserves more texture details and structural information in fused images than advanced fusion algorithms, reducing spectral artifacts and information loss and performing better in terms of visual quality and objective metrics. Conclusion: The proposed method effectively combines MR and CT image information, allowing the precise localization of tumor region boundaries, assisting clinicians in clinical diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Nephrotic syndrome associated with solid malignancies: a systematic review.
- Author
-
Liu, Shuo, Wan, Yuchen, Hu, Ziyu, Wang, Zhixue, and Liu, Fenye
- Subjects
NEPHROTIC syndrome ,IDIOPATHIC diseases ,DELAYED diagnosis ,TUMOR diagnosis ,CANCER treatment ,PARANEOPLASTIC syndromes ,CANCER remission - Abstract
Background: Nephrotic syndrome (NS) can occur as a paraneoplastic disorder in association with various types of carcinoma. However, paraneoplastic nephrotic syndrome (PNS) is often misdiagnosed as idiopathic nephrotic syndrome or as an adverse effect of oncology treatment, leading to delayed diagnosis and suboptimal treatment. The characteristics of NS associated with solid malignancies are not yet elucidated. We systematically summarized the clinical data for 128 cases of NS combined with solid malignancies with the aim of informing the clinical management of PNS. Methods: We searched the PubMed database for articles published from the date of inception through to October 2023 using the following keywords: "cancer" or "malignant neoplasms" or "neoplasia" or "tumors" and "nephrotic syndrome", "nephrotic" or "syndrome, nephrotic". All data were extracted from case reports and case series, and the extraction included a method for identifying individual-level patient data. Results: A literature search yielded 105 cases of PNS and 23 of NS induced by cancer therapy. The median age at diagnosis was 60 years, with a male to female ratio of 1.8:1. In patients with PNS, manifestations of NS occurred before, concomitantly with, or after diagnosis of the tumor (in 36%, 30%, and 34% of cases, respectively). Membranous nephropathy (49%) was the most prevalent renal pathology and found particularly in patients with lung, colorectal, or breast carcinoma. Regardless of whether treatment was for cancer alone or in combination with NS, the likelihood of remission was high. Conclusion: The pathological type of NS may be associated with specific malignancies in patients with PNS. Prompt identification of PNS coupled with suitable therapeutic intervention has a significant impact on the outcome for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Assessment of Tubo-Ovarian Abscess Using Diffusion-Weighted Magnetic Resonance Imaging – a Literature Review.
- Author
-
Ferenc, Thomas and Popić, Jelena
- Subjects
- *
OVARIAN tumors , *TUMOR diagnosis , *DIFFUSION magnetic resonance imaging - Abstract
Aim: To evaluate systematically the magnetic resonance imaging (MRI) features of tubo-ovarian abscess (TOA), the efficacy of diffusion-weighted imaging (DWI) in the assessment of TOA, and the differentiation of TOA from ovarian masses. Material and methods: PubMed/MEDLINE, Web of Science, and ResearchGate were searched with keywords: Tubo-ovarian abscess and Diffusion-weighted magnetic resonance imaging. No restrictions regarding the language or publication year were applied. Inclusion criteria regarded research papers evaluating the role of MRI and DWI in the assessment of TOA, and the differentiation of TOA from ovarian tumours. Studies appearing to meet inclusion criteria were reviewed in full. Results: A total of 14 studies were included. TOA is usually presented as a multilocular, cystic, pelvic mass with a heterogeneously high signal on T2- weighted (T2W) and low signal on T1-weighted (T1W) images with the “penumbra sign” on T1W images. Following contrast administration, septal and thick wall rim enhancement could be visualized. TOA usually demonstrated hyperintensity on DWI and hypointensity on ADC maps with lower ADC values of cystic, and higher ADC values of solid components compared to ovarian malignancy. TOA was smaller in size, and invasion into adjacent organs and tubal dilatation were more frequent in TOA than in ovarian neoplasms. In comparison to other methods, DWI possessed the highest sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in differentiating TOA from adnexal tumours. Conclusions: The addition of DWI with ADC values improves the detection, characterization, and overall diagnostic accuracy of TOA and its distinction from ovarian malignancy. The combination of DWI with MRI in the assessment of TOA is obligatory. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. The challenge of survivors of gynecological carcinomas: a retrospective study on occurrence of second tumors.
- Author
-
Guo, Jianbin, Wang, Hao, Zou, Xueke, Huang, Roujie, Liang, Zhiyong, and Liang, Shuo
- Subjects
- *
VULVAR cancer , *THYROID cancer , *CARCINOMA , *TUMORS , *BLADDER cancer , *TUMOR diagnosis , *OVARIAN cancer - Abstract
Objective: To clarify the epidemiologic characteristics and risk of other tumors in survivors of gynecological tumors. Materials and methods: This is a retrospective study based on the Surveillance, Epidemiology, and End Results database (SEER). Results: The morbidity of other malignant tumors in patients with gynecological cancer was 8.07%. The most common subsequent tumors are breast, lung, colorectal, thyroid, and bladder cancers. Taking the incidence rate of the general population as reference, the second tumor with the highest relative risk in patients with cervical cancer is vulvar cancer. Bladder cancer is the second tumor with the highest relative risk value both in patients with corpus and ovarian cancer. The median period from the diagnosis of the initial tumor to the diagnosis of the second tumor was 5 years. Most patients with other tumors following gynecological cancer showed worse prognosis than patients with gynecological tumors only. However, thyroid cancer following ovarian cancer is a protective factor in survival. Conclusion: Patients with gynecological tumors have a significantly higher risk of malignant tumors in other systems compared to ordinary population. It is necessary to be vigilant against subsequent high-risk tumors and tumors with poor prognosis within 5 years of initial diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Single-handed versus multiple-handed general practices: A cross-sectional study of quality outcomes in England.
- Author
-
Holdroyd, Ian, Chadwick, William, Harvey-Sullivan, Adam, Bartholomew, Theodore, Massou, Efthalia, Tzortziou Brown, Victoria, and Ford, John
- Subjects
- *
TREATMENT of diabetes , *TUMOR diagnosis , *GROUP medical practice , *CROSS-sectional method , *HEALTH services accessibility , *FAMILY medicine , *HYPERTENSION , *EMERGENCY room visits , *MEDICAL office management , *PRIMARY health care , *MEDICAL care , *CONTINUUM of care , *CONFIDENCE , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *AGE distribution , *HEALTH care reform , *PROFESSIONS , *HEALTH outcome assessment , *PATIENT satisfaction , *PUBLIC health , *LABOR discipline , *CONFIDENCE intervals , *DATA analysis software , *JOB performance , *LABOR supply , *REGRESSION analysis - Abstract
Objectives: As general practice increasingly moves towards large group practices, there is debate about the relative benefits, safety and sustainability of different care delivery models. This study investigates the performance of single-handed practices compared to practices with multiple doctors in England, UK. Methods: Practices in England with more than 1000 patients were included. Workforce data and a quality control process classified practices as single-handed or multiple-handed. Outcomes were (i) GP patient survey scores measuring access, continuity, confidence in health professional and overall satisfaction; (ii) reported diabetes and hypertension outcomes; and (iii) emergency department presentation rates and cancer detection (percentage of cancers diagnosed by a 2-week wait). Generalised linear models, controlling for patient and practice characteristics, compared outcomes in single and multiple-handed practices and assessed the effect of GP age in single-handed practices. Results: Single-handed practices were more commonly found in areas of high deprivation (41% compared to 20% of multiple-handed practices). Single-handed practices had higher patient-reported access, continuity and overall satisfaction but slightly lower diabetes management and cancer detection rates. Emergency department presentations were higher when controlling for patient characteristics in single-handed practices but not when also controlling for practice rurality and size. Increased deprivation was associated with lower performance in seven out of eight outcomes. Conclusions: We found single-handed practices to be associated with high patient satisfaction while performing slightly less well on selected clinical outcomes. Further research is required to better understand the association between practice size, including increasing multidisciplinary working, on patient experience and outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Multi‐scale consistent self‐training network for semi‐supervised orbital tumor segmentation.
- Author
-
Wang, Keyi, Jin, Kai, Cheng, Zhiming, Liu, Xindi, Wang, Changjun, Guan, Xiaojun, Xu, Xiaojun, Ye, Juan, Wang, Wenyu, and Wang, Shuai
- Subjects
- *
SUPERVISED learning , *COMPUTED tomography , *EYE diseases , *TUMOR diagnosis , *GAUSSIAN mixture models ,EYE-socket tumors - Abstract
Purpose: Segmentation of orbital tumors in CT images is of great significance for orbital tumor diagnosis, which is one of the most prevalent diseases of the eye. However, the large variety of tumor sizes and shapes makes the segmentation task very challenging, especially when the available annotation data is limited. Methods: To this end, in this paper, we propose a multi‐scale consistent self‐training network (MSCINet) for semi‐supervised orbital tumor segmentation. Specifically, we exploit the semantic‐invariance features by enforcing the consistency between the predictions of different scales of the same image to make the model more robust to size variation. Moreover, we incorporate a new self‐training strategy, which adopts iterative training with an uncertainty filtering mechanism to filter the pseudo‐labels generated by the model, to eliminate the accumulation of pseudo‐label error predictions and increase the generalization of the model. Results: For evaluation, we have built two datasets, the orbital tumor binary segmentation dataset (Orbtum‐B) and the orbital multi‐organ segmentation dataset (Orbtum‐M). Experimental results on these two datasets show that our proposed method can both achieve state‐of‐the‐art performance. In our datasets, there are a total of 55 patients containing 602 2D images. Conclusion: In this paper, we develop a new semi‐supervised segmentation method for orbital tumors, which is designed for the characteristics of orbital tumors and exhibits excellent performance compared to previous semi‐supervised algorithms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Extraovarian seromucinous borderline tumor: Case report and literature review.
- Author
-
Sakata, Mina, Mabuchi, Seiji, Maeda, Michihide, Nagata, Shigenori, Tanaka, Junichiro, and Kamiura, Shoji
- Subjects
- *
TUMOR diagnosis , *HYSTERECTOMY , *PAPILLARY carcinoma , *RARE diseases , *POSTMENOPAUSE , *TUMOR markers , *TREATMENT effectiveness , *ENDOMETRIOSIS , *TUMOR antigens ,TUMOR surgery ,CERVIX uteri tumors - Abstract
Seromucinous borderline tumors (SMBT) are papillary neoplasms without invasive capabilities. Originally categorized as ovarian tumors, SMBT, being an endometriosis‐related tumor, can manifest beyond the ovaries. To date, only four cases of extraovarian SMBT have been documented in literature. In this report, we present our experience with the first case of SMBT in the uterine cervix, which exhibited highly elevated CA19‐9 levels. The patient, initially clinically diagnosed with cervical cancer, underwent treatment with radical hysterectomy and was later pathologically diagnosed with SMBT of the uterine cervix. While extraovarian SMBT, especially in the uterine cervix, is extremely rare, this condition should be considered in patients with cervical masses lacking pathological evidence of malignant disease but displaying elevated CA19‐9 levels. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Artificial Intelligence in Cancer Clinical Research: II. Development and Validation of Clinical Prediction Models.
- Author
-
Lyman, Gary H. and Kuderer, Nicole M.
- Subjects
- *
TUMOR risk factors , *TUMOR diagnosis , *SERIAL publications , *RISK assessment , *PREDICTION models , *CLINICAL medicine research , *ARTIFICIAL intelligence , *ONCOLOGY , *TUMORS ,RESEARCH evaluation - Published
- 2024
- Full Text
- View/download PDF
47. Tumor-Derived Extracellular Vesicles as Liquid Biopsy for Diagnosis and Prognosis of Solid Tumors: Their Clinical Utility and Reliability as Tumor Biomarkers.
- Author
-
Dabral, Prerna, Bhasin, Nobel, Ranjan, Manish, Makhlouf, Maysoon M., and Abd Elmageed, Zakaria Y.
- Subjects
- *
TUMOR diagnosis , *EXTRACELLULAR vesicles , *PREDICTIVE tests , *CELL physiology , *MICRORNA , *LIPIDS , *TUMOR markers , *DNA , *MESSENGER RNA , *TUMORS , *MACHINE learning , *DISEASE progression ,BODY fluid examination - Abstract
Simple Summary: The ongoing research of extracellular vehicles (EVs including exosomes, ectosomes, and apoptotic bodies) is gaining momentum to understand these vesicles' biology and clinical applications in cancer disease. The current limitations of using standard tumor biomarkers warrant the development of novel and reliable biomarkers to meet clinical needs. Exosomes are used as tumor biomarkers, for targeted therapy, for vaccine development, and as a vehicle for drug delivery. Here, we summarized the current approaches for different methods of EV isolation and EV cargo compositions, such as nucleic acids, proteins, and lipids. The unique cargo composition of exosomes makes it a potential candidate for liquid biopsies in the diagnosis and prognosis of cancer patients. Furthermore, the review highlights the use of machine learning algorithms to analyze complex EV datasets and create more robust models for biomarker discovery. Early cancer detection and accurate monitoring are crucial to ensure increased patient survival. Recent research has focused on developing non-invasive biomarkers to diagnose cancer early and monitor disease progression at low cost and risk. Extracellular vesicles (EVs), nanosized particles secreted into extracellular spaces by most cell types, are gaining immense popularity as novel biomarker candidates for liquid cancer biopsy, as they can transport bioactive cargo to distant sites and facilitate intercellular communications. A literature search was conducted to discuss the current approaches for EV isolation and the advances in using EV-associated proteins, miRNA, mRNA, DNA, and lipids as liquid biopsies. We discussed the advantages and challenges of using these vesicles in clinical applications. Moreover, recent advancements in machine learning as a novel tool for tumor marker discovery are also highlighted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Integrating Omics Data and AI for Cancer Diagnosis and Prognosis.
- Author
-
Ozaki, Yousaku, Broughton, Phil, Abdollahi, Hamed, Valafar, Homayoun, and Blenda, Anna V.
- Subjects
- *
TUMOR diagnosis , *GENOMICS , *ARTIFICIAL intelligence , *RADIOMICS , *EPIGENOMICS , *GENE expression , *PROTEOMICS , *TUMORS , *MACHINE learning - Abstract
Simple Summary: Cancer remains one of the leading causes of death worldwide, which emphasizes the need for its early and accurate diagnosis and prognosis. Our review explores AI's potential in this field, analyzing 89 recent studies from 2020 through 2023. Specifically, these studies included AI applications for the analysis of multi-omics data: radiomics, pathomics, clinical records, and lab data. Notably, eight studies combined diverse omics data types (genomics, transcriptomics, epigenomics, and proteomics). Integration of AI for the analysis of clinical and omics data contributes to a significant advancement and is essential for safe clinical implementation. Cancer is one of the leading causes of death, making timely diagnosis and prognosis very important. Utilization of AI (artificial intelligence) enables providers to organize and process patient data in a way that can lead to better overall outcomes. This review paper aims to look at the varying uses of AI for diagnosis and prognosis and clinical utility. PubMed and EBSCO databases were utilized for finding publications from 1 January 2020 to 22 December 2023. Articles were collected using key search terms such as "artificial intelligence" and "machine learning." Included in the collection were studies of the application of AI in determining cancer diagnosis and prognosis using multi-omics data, radiomics, pathomics, and clinical and laboratory data. The resulting 89 studies were categorized into eight sections based on the type of data utilized and then further subdivided into two subsections focusing on cancer diagnosis and prognosis, respectively. Eight studies integrated more than one form of omics, namely genomics, transcriptomics, epigenomics, and proteomics. Incorporating AI into cancer diagnosis and prognosis alongside omics and clinical data represents a significant advancement. Given the considerable potential of AI in this domain, ongoing prospective studies are essential to enhance algorithm interpretability and to ensure safe clinical integration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Canine Cancer Diagnostics by X-ray Diffraction of Claws.
- Author
-
Alekseev, Alexander, Yuk, Delvin, Lazarev, Alexander, Labelle, Daizie, Mourokh, Lev, and Lazarev, Pavel
- Subjects
- *
TUMOR diagnosis , *DOG diseases , *RECEIVER operating characteristic curves , *COMPUTED tomography , *EARLY detection of cancer , *DESCRIPTIVE statistics , *ANIMAL experimentation , *MACHINE learning , *ALGORITHMS , *BIOMARKERS , *SENSITIVITY & specificity (Statistics) - Abstract
Simple Summary: Canine cancer is a leading cause of dog mortality. In this study, we examine the hypothesis that the structure of keratin changes when cancer develops in the patient. We use X-ray diffraction of dog claws to detect these changes, finding that the modifications of the intermolecular distances are the most significant. Machine learning algorithms are utilized for cancer/non-cancer diagnostics, achieving a balanced accuracy of 85% for the blind group. Our research suggests that the changes in keratin structure can be tracked by X-ray diffraction, offering a potential tool for non-invasive cancer diagnostics. This could have significant implications for the early detection and treatment of canine cancer, potentially saving many lives. Moreover, this approach can be extended to human cancer detection. We report the results of X-ray diffraction (XRD) measurements of the dogs' claws and show the feasibility of using this approach for early, non-invasive cancer detection. The obtained two-dimensional XRD patterns can be described by Fourier coefficients, which were calculated for the radial and circular (angular) directions. We analyzed these coefficients using the supervised learning algorithm, which implies optimization of the random forest classifier by using samples from the training group and following the calculation of mean cancer probability per patient for the blind dataset. The proposed algorithm achieved a balanced accuracy of 85% and ROC-AUC of 0.91 for a blind group of 68 dogs. The transition from samples to patients additionally improved the ROC-AUC by 10%. The best specificity and sensitivity values for 68 patients were 97.4% and 72.4%, respectively. We also found that the structural parameter (biomarker) most important for the diagnostics is the intermolecular distance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Eosinophilic Cells in Ovarian Borderline Serous Tumors as a Predictor of BRAF Mutation.
- Author
-
Badlaeva, Alina, Tregubova, Anna, Palicelli, Andrea, and Asaturova, Aleksandra
- Subjects
- *
TUMOR diagnosis , *OVARIAN tumors , *PRECANCEROUS conditions , *FISHER exact test , *RETROSPECTIVE studies , *CYTOREDUCTIVE surgery , *DESCRIPTIVE statistics , *IMMUNOHISTOCHEMISTRY , *MEDICAL records , *ACQUISITION of data , *GENE expression profiling , *TUMORS , *GENETIC mutation , *STAINS & staining (Microscopy) , *TRANSFERASES , *SENSITIVITY & specificity (Statistics) , *GENETIC testing ,TUMOR genetics - Abstract
Simple Summary: Ovarian serous borderline tumor (SBT) is a known precursor of low-grade serous carcinoma, and it has been reported that about 50% of SBTs are BRAF-mutated and that these tumors have a better prognosis. Therefore, early identification of the mutation is important for accurate treatment and follow-up of patients with SBT. It has been shown that eosinophilic cells (ECs) can be a histologic sign of a BRAF mutation. Therefore, the aim of our retrospective study was to evaluate the interobserver reproducibility for these cells. A BRAFV600E mutation was found in 45% of cases. The interobserver reproducibility in the assessment of ECs was substantial. The sensitivity and specificity for predicting the mutation were 79% and 91%, respectively, so ECs in ovarian SBTs can be used for initial screening of the BRAFV600E mutation to stratify patients and establish a prognosis. According to recent reports, ovarian serous borderline tumor (SBT) harboring the BRAF V600E mutation is associated with a lower risk of progression to low-grade serous carcinoma. Preliminary observations suggest that there may be an association between eosinophilic cells (ECs) and the above-mentioned mutation, so this study aimed to evaluate interobserver reproducibility for assessing ECs. Forty-two samples of SBTs were analyzed for ECs with abundant eosinophilic cytoplasm. Immunohistochemical staining and genetic pro-filing were performed in all cases to verify the BRAF V600E mutation. A BRAF V600E mutation was found in 19 of 42 (45%) cases. Inter-observer reproducibility in the assessment of ECs was substantial (κ = 0.7). The sensitivity and specificity for predicting the mutation were 79% and 91%, respectively. Patients with BRAF-mutated SBTs were significantly younger than those without mutation (p = 0.005). SBTs with BRAF mutation were less likely to be accompanied by non-invasive implants than wild-type SBT: 12% (2/17) versus 33% (6/18). Seven cases were excluded due to incomplete cytoreductive surgery. Nevertheless, Fisher's exact test showed no significant differences between the two groups (p = 0.228). Overall, this study strengthens the idea that ECs in ovarian SBTs may represent a mutation with prognostic significance, which can serve as a primary screening test for BRAF V600E mutation in this pathologic entity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.